PCSA - Processa Pharmaceuticals Inc

https://www.processapharmaceuticals.com

Recent News

Processa Pharmaceuticals ( PCSA ) Shares Soar 150% On Gastroparesis Drug Deal - Processa Pharmaceuticals ( NASDAQ:PCSA )

Benzinga • 2 months, 4 weeks ago • score: 0.45

Processa Pharmaceuticals' stock is surging after licensing a gastroparesis drug to Intact Therapeutics. The deal promises milestone payments and royalties for Processa. 9 Out of the Last 10 Summers this "Power Pattern" Delivered Winners - Get The Details Now.

Bullish

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

GlobeNewswire • 7 months, 1 week ago • score: 0.16

HANOVER, Md., Feb. 07, 2025 ( GLOBE NEWSWIRE ) -- Processa Pharmaceuticals, Inc. ( Nasdaq: PCSA ) ( Processa or the Company ) , a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients with unmet medical needs in the United States. The company is headquartered in Hanover, Maryland.

52W High

$1.50

52W Low

$0.15

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.35

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.14

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.42

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

12.08%

Institutions (25–75% balanced)

5.99%

Shares Outstanding

50,349,000

Float

42,546,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-2.31

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-2.12%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—